Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_assertion type Assertion NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_head.
- NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_assertion description "[CRF resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_provenance.
- NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_assertion evidence source_evidence_curated NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_provenance.
- NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_assertion SIO_000772 19878707 NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_provenance.
- NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_assertion wasDerivedFrom ctd_human-20130708 NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_provenance.
- NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_assertion wasGeneratedBy ECO_0000218 NP30908.RAg0Lzcj5F9PduFA45q-agBK9v6iTzK9d1ug3Hya1Nl0g130_provenance.